TW407152B - Process for the preparation of 4-oxoimidazolinium salts - Google Patents
Process for the preparation of 4-oxoimidazolinium salts Download PDFInfo
- Publication number
- TW407152B TW407152B TW086101034A TW86101034A TW407152B TW 407152 B TW407152 B TW 407152B TW 086101034 A TW086101034 A TW 086101034A TW 86101034 A TW86101034 A TW 86101034A TW 407152 B TW407152 B TW 407152B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- patent application
- scope
- item
- strong acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical class O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 239000002253 acid Substances 0.000 claims abstract description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 150000001450 anions Chemical class 0.000 claims abstract description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000001486 argon compounds Chemical class 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 229920006395 saturated elastomer Polymers 0.000 abstract description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 11
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 10
- 229960004448 pentamidine Drugs 0.000 description 10
- -1 phenylthiomethyl Chemical group 0.000 description 10
- 239000007789 gas Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002462 imidazolines Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000005533 tritiation Methods 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- JCLSEQJEXYHVTC-UHFFFAOYSA-N 2-amino-2-methylbutanenitrile Chemical compound CCC(C)(N)C#N JCLSEQJEXYHVTC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
407152 A7 B7 五、發明説明(1 ) 本發明係關於一種製備4_氧咪唑琳鹽之方法,其一般 分子結構式如下: R1
Ο 經濟部中央標準局員工消費合作杜印製 在其中R1和R2可為互相獨立的一個至十個碳原子的烷基, 二個至十個碳原子的烯基,三個至七個碳原子的環烷基 或任意選擇取代基的芳基、芳烷基、雜芳基或雜芳烷基 ,或R1和R2和它們鍵結在一起的碳原子形成一個三元至七 元的飽和或不飽和的碳環或雜環,R3是一個至十個碳原子 的烷基,二個至十個碳原子的烯基,三個至七個碳原子 的環烷基或任意選擇取代基的芳基、芳烷基或雜芳基, 而A·為一強酸的陰離子。在上文及下文中,一個至十個碳 原子的烷基其意義為直鏈和支鏈的第一級、第二級和第 三級具有一個至十個碳原子的烷基〇相對地,二個至十 個碳原子的烯基其意義為直鏈和支鏈的第一級、第二級 和第三級在任意位置具有一個或多個雙鍵的碳氫基。芳 基其意義為單環或多環的芳基族,特別是苯基和萘基。芳 烷基族其意義為具芳基族取代基的碳數較低的烷基,特 別是苯甲基和苯乙基。雜芳基族其意義為特別是吱喃基 族或3-硫茂基族(苯硫基族),而相對地,雜芳烷基其意 義為例如。夫喃甲基族或苯硫甲基族。芳基、芳烷基、雜 (請先閱讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家標準(CNS ) A4規格(210Χ2^7公釐) 經濟部中央橾準局負工消費合作社印聚 s 一 407152 - - _ 五、發明説明(2 ) 芳基或雜芳烷基族可任意選擇地具一個或多個取代基, 例如一個至四個碳原子的燒基、一個至四個碳原子的燒 乳基或由素。 此類化合物或2-咪唑琳-4-酮(1务咪唑-5 (4扇)-酮 )’為以這些鹽類為依據的藥物活性物質合成中重要的中 間體,例如血管緊縮素II對抗劑(WO-A 91/14679, US-A 5 424 450) »迄今,這些化合物係以例如下列方法 製備,將α-氨基骑醯化至相對的醯胺基骑(=α-醯氨基 骑’也就是「脂肪族化合物」),將骑基族酸水解至氨 基甲醯族和接著的鹼催化的環化反應至產物胺基醯胺( US-A 5 424 450,計畫3)。醯化反應和水解的順序可互 相掉換(WO-A 91/14679,第25-26頁)。這些方法的缺 點為必須在酸性和驗性的反應條件中轉換,每次轉換需 要中和反應,而導致產生大量的相對的廢物鹽。 於是本發明的目標為提供一種比較簡單的方法,其產 生比較少的廢物。 根據本發明申請專利範圍第1項之方法,此目標是可 達成的。 意外地,4-氧咪唑琳鹽(I)被發現可以直接從α-醯 氨基婿獲得,其一般分子結構式如下: 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) -6 - (請先聞讀背面之注$項再填寫本頁)
、-iT -峻! 407152 Α7 Β7 五、發明説明(3 ) R1 < Ν==Ξ C ---ΝΗ (諳先閱讀背面之注意事項再填寫本頁} R2 其中R1,R2和R3如上文所定義,在一非水溶劑中,其中有 碳數比較低的醇和一種強酸,其一般分子結構式為, 其中A或陰離子A·如上文所定義’在一個步驟,不需要分 離中間體和中和反應步驟》 〇醯氨基骑(Π)可用已知的方法製備,.例如以史垂 克反應(Strecker Reaction)將相對的羰基化合物Ri_c ( =0) -R2和氫氰酸及氨一起反應,其所產生的α_氨基骑 和氣羧酸R3C0C1接著進行醯化反應。 無機酸(礦物酸)和肴機酸,例如硫酸,皆為合適的 強酸HA » 比較喜好使用的酸為一族群含有南化氳、硫酸、甲酸 、三氟醋酸和甲磺酸。其中特別喜好的為鹽酸。 經濟部中央標準局貝工消費合作社印製 比較喜好的強酸的總使用量為1至2當量的每一莫耳的 起始物質,比較喜好的選擇使用量為us15當量。 至於’比較喜好使用的非水溶劑為一族群含有芳族碳 氫化合物,例如苯、甲苯或二甲苯,或一族群含有鹵化 碳氫化合物,例如二氯甲燒。 比較喜好的特別具體方法是同時使用一碳數比較低的 醇和非水溶劑。甲醇、乙醇、丙醇、丁醇和異丙醇特別 本紙張尺度通用宁國ϋ豕標华(CNS ) Λ4規格(21〇χ297公廣) 經濟部中央標準扃貝工消费合作社印袈 407152 at ^__B7 五、發明説明(4 ) 合適此一目的β 根據本發明,4-氧咪唑琳鹽的製備方法比較喜 好使用螺環化合物,在其中R1和R2和它們鍵結在一起的碳 原子,形成環戊烷或環己烷環- 在製備4-氧咪唑琳鹽(I)時也比較喜好使用R3為一 個至六個碳原子的烷基族。 有利的反應溫度為0至120°C,較佳的溫度為2〇至1〇〇 〇C。 當然,以鹼將4·氧咪唑琳鹽(1)轉換成相對的咪唑 嚇*-4-嗣也在本發明的結構中。 下列實例說明本發明之製備方法是如何完成的,但不 因此意味有任何界限。 實例1 2-丁基-1,3-二氮雜螺壬娱X2-缔-4-酮單氣化氫 (I ’ Ι^+Ι12 = ·((:Η2)4-,R3 =正.丁基) 新鮮製備的9.39公克(39毫莫耳)的氣化氫在乙醇( 15.15%,重量百分比)溶液被加入68〇公克(3〇毫莫耳 )的廣_ (1-氰基環戊基)戊酿胺(以史垂克合成法製備 將環戊酮轉換成1-氨基環戊骑,並以戊醯氣加以醯化, 含量85.7%)在28公克的無水乙醇溶液中。此混合溶液在 氮氣中被加熱至50°C,並在此溫度中攪拌3丨小時。然後 此溶液被冷卻至1°C,並在此溫度中被放置i小時。沉澱 出的產物被過濾出來,並以10毫升冰冷的乙醇清洗和以 40°C/24毫巴壓力下加以乾燥。 本紙張尺度適用中國國家標準(CNS ) A4規iT( 2丨〇>^97公楚)---- -8 - (請先閲讀背面之注意事項再填寫本頁) -訂 線! 407152 A7 B7 五、發明説明(5 產率.4.05公克(58%)的無色晶體,含量98 3% ( 以高效液相層析分析,HPLC)。 實例2 2-丁基-1,3-二氮雜螺壬烷_2_缔_4_嗣單氣化氫 (I ’ R +R2=-(CH2)4·,R3=正丁基) -含有6.88公克(3〇毫莫耳)的备(1-氰基環戊基) 戊醯胺(含量84.7%)溶液以15分鐘的時間在7(rc和氮氣 下被一滴一滴地加入一含有9 84公克(45毫莫耳)氣化氫 的16.7%丙醇溶液和1171公克的無水丙醇的混合溶液中 ,而有一固體沉澱出來。此混合溶液在7〇它繼續被攪拌 1.7小時後,冷卻至rc並在此溫度下放置丨小時。產物被 過濾出來,並以10毫升冰冷的丙醇清洗和以4〇〇c/24毫巴 壓力下加以乾燥》 產率:5_74公克(79%)的無色晶體,含量95.4% ( 滴定分析)^ 紅外線光譜(溴化鉀):^ = 1779 ; 1642 ; 1517 cm」 〇 經濟部中央標準局貝工消费合作社印裝 (請先聞讀背面之注意事項再填寫本頁) ·"-- 氫核磁共振光譜(二甲亞石風-d6) : δ=13.64 (s, 2Η) ; 2.80 (m,2Η) ; 1.7-2.0 (m,10Η) ; 1.34 (m , 2H) ; 〇別(t,J=7 3Hz,3H)。 氮十五核磁共振光譜(二甲亞石風-d6) : δ=-211·8 ; •219.6 (榡準:乙醯替苯胺)。 實例3 2-丁基-1,3-二氮雜螺壬烷_2_埽_4_酮單氣化氫 經濟部中央標準局員工消費合作社印裝 A7 _________B7 五、發明説明(6 ) (I,R丨+ R2=-(CH2)4-,R3 =正-丁基) 6.88公克(30毫莫耳)之扇_ (1•氰基環戊基)戊醯胺 (含量84.7%)在氮氣中和—含有273公克的無水異丙醇 及新鮮製備的9.92公克(39毫莫耳)氣化氫的14.33%異 丙醇溶液的混合溶液中在室溫下攪拌44小時。然後此溶 液被冷卻至rc,並在此溫度中被放置半小時。沉殿出的 產物被過遽出來’並以10毫升冰冷的異丙醇清洗和以4〇 °C/24毫巴壓力下加以乾燥。 產率:3.04公克(44%) ’含量99.7% (以高效液相 層析分析)。 實例4 2-丁基-1,3-二氮雜螺壬烷-2-烯-4-嗣單氣化氫 (I,1^ + 厌2=_(〇12)4_,R3 =正-丁基) 6.88公克(30毫莫耳)之扇-(i_氰基環戊基)戊醯胺 (含量84.7%),16.66公克的無水丁醇及新鮮製備的 10.06公克(39毫莫耳)氣化氫的14.13%丁醇溶液在氮氣 中及攪拌下被加熱至回流點(預熱的油浴),當内部溫 度到達大約100°C時產物即沉殿出來。經過2,9小時之回流 (115°C) ’此混合溶液被冷卻至1°C,並在此溫度中被 放置1小時。沉;殿出的產物被過濾出來,並以1〇毫升冰冷 的丁醇清洗和以40°C/24毫巴壓力下加以乾燥。 產率:4_93公克(66%),含量92.7% (以高效液相 層析分析)。 實例5 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) -10- (請先閱讀背面之注意事項再填寫本頁) 、-»- 4t— 經濟部中央標準局員工消費合作社印聚 407152 at __B7 _ 五、發明説明(7 ) 2-氨基-2-甲基丁腈 40.0公克(800毫莫耳)之氰化鈉被溶於78毫升的水 。一溶液含有47.5公克(880毫莫耳)之氯化銨在一70毫 升之濃氨水溶液(0.92莫耳的氨)和118毫升水的混合溶 液在室溫和氮氣中被加入上述之氰化鈉溶液。一混合溶 液含有51.8公克(714毫莫耳)的丁酮和76毫升的甲醇( 以分子篩加以脫水)被一滴一滴地在20-25。(:(水浴)下 加入上述之溶液。此反應混合物在室溫中被攪拌約2小時 ,然後被加熱至60°C,並在此溫度被放置約1小時。冷卻 後,此反應混合物以一次200毫升之後再以兩次100毫升 的二氣甲烷萃取。所有的有機層以20公克硫酸鈉脫水, 過濾後以二氣甲烷稀釋至700公克的溶液。此產物溶液被 用於醯化反應而不需要後續處理步驟。 產率:94% (以氣相層析分析,GC)。 實例6 農-(1-氰基-1-甲基丙基)戊醯胺 (II,rL乙基,R2=甲基,R3=正·丁基) 在室溫和氮氣中,39.6公克(389毫莫耳)的三乙基胺被 加入於350公克的2_氨基-2-甲基丁腈在二氣甲烷的溶液中 (從實例5,最高量357毫莫耳),而後在l〇-25°C (冷卻 )下47.9公克(389毫莫耳)的戊醯氯以1小時的時間一滴 一滴地被加入此溶液中,而一固體(三乙基氣化按)被 沉澱出來。當加完戊醯氣後,此反應混合物在室溫中被 繼續攪拌2小時。而後加入100毫升的水則此溶液之液相 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 20公釐) (請先閣讀背面之注意事項存填寫本貰) 訂 經濟部中央樣準局員工消費合作社印裝 407152 a? _B7______ 五、發明説明(8 ) 被分層。有機層以100毫升1 N (當量濃度)的鹽酸’然後 以100毫升的水清洗,再以20公克的硫酸鈉脫水’最後在 嘴水流真空(water-jetvacuum)下加以濃縮。 產率:50.2公克的油,含量(以氣相層析分析)86% (相當於66%之理論值)。 紅外線光譜(薄膜):? =3305 ; 2230 ; 1656 ; 1535 cm'1 ° 氫核磁共振光譜(二甲亞石風-d6) : δ = 8.13 (s,1H );2.14 (t’《/=7.3 Hz,2Η) ; 1.8 (m,2H) ; 1.52 (s ,3H) ; 1.4-1.5 (m,2H) ; 1.29 (m,2H) ;0_98(t’ 7.3 Hz,3H) ; 0.88 (t,*7=7.2 Hz,3H)。 實例7 2-丁基-4-乙基>4-甲基-1|咪唑-5 (4扃)_酮氯化氫 (I ’ rL乙基,R2=甲基,R3 =正-丁基,A_=氯離子) 從實例6的19.05公克(90毫莫耳)的農 (1·氰基小 甲基丙基)戊醯胺在一混合溶液含有25.6公克16.7%的氯 化氫在丙醇的溶液(117毫莫耳之氣化氫)和53.8公克的 丙醇(以分子篩加以脫水),在30。(:和氮氣下被攪拌6.5 小時。所產生的透明黃色溶液然後被放置於冰箱中過夜 。沉搬出來的晶體被過濾出來,並以10毫升冰冷的丙醇 清洗和以40°C/24毫巴壓力下加以乾燥。 產率·· 5.38公克(27%)的白色晶體,含量995% ( 以高效液相層析分析)。 紅外線光譜(溴化鉀):;:=1779 ; 1638 ; 1519 cnfi 本紙張尺度適财關家標見格(; (請先閱讀背面之注意事項再填寫本頁)
*1T 气__ 經濟部中央標準局負工消費合作杜印製 407152 at B7 五、發明説明(9 ) 〇 氫核磁共振光譜(二甲亞石風-d6) : δ=13.7ΐ (S, 1Η) ; 2.87 (m » 2H) > 1.7-1.8 (m » 4H) » 1.43 (s » 3H) ;1.37(m>2H) ; 0.92 (f 7=7.4 Hz » 3H); 0.83 (t,*7=7.3 Hz,3H)。 氮十五核磁共振光譜(二甲亞石風-d6) : 3 = -215.4 ; -217.7。 實例8 2-氣基-2-苯基·丙骑 40.0公克(800毫莫耳)的氰化鈉和47.5公克(880毫 莫耳)的氯化銨在氮氣下被懸浮於196毫升的甲醇中。一 混合溶液含有87.5公克(714毫莫耳)的乙醯苯和76毫升 的甲醇(以分子篩加以脫水)以15分鐘的時間在室溫中 被一滴一滴地加入上述溶液。此反應混合溶液在室溫中 繼續被攪拌1小時後加熱至4〇°C,保持在此溫度5.5小時後 在22°C中繼續被攪拌2天。所產生的橘色懸浮液以一細孔 玻璃過濾器加以過濾,而濾出液在真空下和最高溫為35 。(:中被濃縮至原有體積的四分之一後再過濾。這遽出液 (約100公克)被以二乙醚稀釋至400公克後再過滤一次 。:11.4公克(1.1當量)的氯化氫以70分鐘的時間加入此 產生的透明橘-紅色的溶液後一淡色固體沉澱出來。此混 合溶液被放置於冰箱中過夜後,上層清液被從沉殿物中 輕輕倒出。此沉澱物以50毫升的二乙醚清洗後被溶於 毫升的水。此水溶液(酸鹼質約2.5)被以濃氫氧化鈉溶 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X20公釐) (請先閱讀背面之注意事項再填寫本頁) ,ιτ 嗖! 407^52 at _________B7 五、發明説明(10 ) 液調整至酸鹼質8.7後’以三次100毫升的二乙醚萃取。 全部的二乙醚萃取液以20公克的硫酸鈉脫水後在真空下 蒸發。殘留物被懸浮於兩次15毫升的甲苯後,在真空下 濃縮至乾。 產率:56.2公克’含量(以氫核磁共振光譜分析) 83% (相當於45%的理論值,以乙醯苯為依據)。 紅外線光譜(氣化鈉):5=3378 ; 3313 ; 2224 cm·1 〇 氫核磁共振光譜(三氣重氫甲烷):δ = 7.63-7.68 ( m,2H) ; 7.30-7.43 (m,3H) ; 2.08 (s,2H) ; 1.74( s ’ 3H)。 實例9 農-(1-氰基-1-苯基乙基)戎睡胺 (II ’ R =冬基,=甲基,R3 =正-丁基) 經濟部中央標準局負工消费合作社印繁 46.1公克(375毫莫耳)的戊醯氯以55分鐘的時間在 12-23°〇(冷卻)下和氮氣中被一滴一滴地力11入55.8公克 的2_氨基-2-苯基丙猜(從實例8,約0.34莫耳)和38.1公 克(375毫莫耳)的三乙基胺在280公克的二氯甲燒溶液 中則一固體(三乙基氯化銨)被沉澱出來。當加完戊醯 氣後,此反應混合物在室溫中被繼續攪拌2小時。而後加 入100毫升的水則此溶液之液相被分層。有機層以1〇〇毫 升1N (當量濃度)的鹽酸,然後以100毫升的水清洗,再 以20公克的硫酸鈉脫水,最後在喷水流真空和50°C下加 以濃縮。為純化40公克的殘留物(總重量為84.1公克米黃 本纸浪尺度適用中國國家^準(CNS ) A4規格(210Χ;297公廣) ' " -14 - 經濟部中央標準局員工消费合作社印裝 術省52 五、發明説明(11 ) 色的固體)被以從230毫升沸騰的醋酸乙酯/環己烷(70 : 3〇)溶液中再結晶,冷卻至室溫後,以一細孔玻璃過遽 器過濾出來,再以50毫升的環己烷清洗和以4CTC/30毫巴 壓力下加以乾燥。 產率:31.71公克的白色晶體(以粗產物的總重量做 外插法:66.7公克,相當於84%的理論值,以氨基骑為 依據)。 紅外線光譜(溴化鉀):ΐ =2228 ; 1657 ; 1539 cnf1 ο 氫核磁共振光譜(二f亞石風-d6) : δ=7.3_7.4 (m, 5H) ; 7.03 (s,1H) ; 2·15 (t,J=7.6 Hz,2H) ; 1.77 (s,3H) ;l_55(m,2H) ; 1.30 (m,2H) ; 0.89 (t »,/=7.3 Hz > 3H) ° 實例10 2-丁基-4-甲基-4-苯基-1羞-咪唑-5 (4肩)-酮氣化氫 (I,R1==苯基,R2=甲基,R3 =正-丁基,A-=氯離子) 從實例9的8.49公克(30毫莫耳)的扇-(1-氰基-1-苯 基乙基)戊醯胺在一混合溶液含有9.2公克15.5%的氣化 氫在丙醇的溶液(30毫莫耳之氣化氫)和33.3公克的丙醇 (以分子篩加以脫水)和氮氣中被加熱至50°C,並在此 溫度被攪拌3.25小時。所產生的透明黃色的溶液在室溫下 被放置過夜,然後以5〇°C/16毫巴壓力下蒸發至乾。此殘 留物(17.76公克)在室溫中被懸浮於30毫升的丙酮1.25 小時。此懸浮液被以一細孔玻璃過濾器加以過濾後,過 本紙張尺度適用中國國家摞準(CNS)A4規格(2丨公釐) (請先閱讀背面之注意事項再填寫本頁) J*e ! Α7 Β7 407152 五、發明説明(12 ) 濾餅以10毫升的丙酮清洗和以40°c/24毫巴壓力下加以乾 燥。 產率:5.47公克的白色晶體,含量(滴定分析)98% (相當於67%的理論值,以氨基腈為依據)。 紅外線光譜(溴化卸):v=1787 ; 1633,1517 cm1 ο 氫核磁共振光譜(二甲亞石風4) : δ=14·0 (s,2Η );7.3-7.6 (m * 5H) ; 2.99 (t »/=7.5 Hz » 2H) ; 1.7-2.0 (m,2H) ; 1.85 (s,3H) ; 1.38 (m ’ 2H) ; 0.93 (t,*7=7.5 Hz,3H) 〇 氮十五核磁共振光譜(二甲亞石風-d6) : δ = -213.5 ; -220.0。 人請先閱讀背面之注$項再填寫本頁) -* 經濟部中央標隼局貝工消費合作社印«.
Claims (1)
- ——· 、 '* I m in Η、申請專利範圍A8 DO 407152 g| 第86101〇34號卑剎幸申請袁剎範面修正太 I 一種製備4-氧咪唑琳鹽之方法,其一般分子結構式係如 下:其中’ R1、R2為(^至。。烷基,或為選擇性地,任意由 ^至匕烷基、(^至匕烷氧基、或南素取代之苯基,或Rl 、R2與其键結在一起之碳原子,形成一個三元至七元的 飽和碳環; R3為C1至C10烷基; A'為一強酸的陰離子, 其特徵為,一α-醯氨基猜,其一般分子結構式如下:R1 C ---ΝΗ R2 其中,R1、R2及R3如上文之定義,在一非水溶劑中被環 化,其中並有一種碳數較低的醇和一種強酸,其〜般= 予結構式為ΗΑ,其中Α如上文之定義。 乃 2.根據申請專利範圍第1項所述之方法,其特徵為一 1固 ........ 丨丨 圓· , 本紙張尺度適用中國國家樣準(CNS )八4胁(21GX297公釐)—------------ -17-——· 、 '* I m in Η、申請專利範圍A8 DO 407152 g| 第86101〇34號卑剎幸申請袁剎範面修正太 I 一種製備4-氧咪唑琳鹽之方法,其一般分子結構式係如 下:其中’ R1、R2為(^至。。烷基,或為選擇性地,任意由 ^至匕烷基、(^至匕烷氧基、或南素取代之苯基,或Rl 、R2與其键結在一起之碳原子,形成一個三元至七元的 飽和碳環; R3為C1至C10烷基; A'為一強酸的陰離子, 其特徵為,一α-醯氨基猜,其一般分子結構式如下:R1 C ---ΝΗ R2 其中,R1、R2及R3如上文之定義,在一非水溶劑中被環 化,其中並有一種碳數較低的醇和一種強酸,其〜般= 予結構式為ΗΑ,其中Α如上文之定義。 乃 2.根據申請專利範圍第1項所述之方法,其特徵為一 1固 ........ 丨丨 圓· , 本紙張尺度適用中國國家樣準(CNS )八4胁(21GX297公釐)—------------ -17- 3888 CBCD 六、申請專利範圍407152 酸係從-族群含«化氫、硫酸、甲酸、甲續酸和三氣 醋酸中’被選擇使用為強酸HA。 3. 根據申請專利範圍第2項所述之方法,其特徵為,鹽酸 被使用為強酸HA。 4. 根據申請專利範圍第1項所述之方法,其特徵為,一溶 劑係從-族群含有芳族碳氫化合物、或從—族群含有函 化碳氩化合物中,被選擇使用為非水溶劑。 5. 根據申請專利範圍第1項所述之方法,其特徵為,曱醇 、乙醇、丙醇、丁醇或異丙醇,被使用為碳數比較低的 醇和非水溶劑。 6. 根據申請專利範圍第1項所述之方法,其特徵為,被使 用作為α-醯氨基猜(π)的化合物,為一化合物,其中 R1、R2與其鍵結在一起的碳原子,形成環戊烷或環己烷 環。 7_根據申請專利範園第1項所述之方法,其特徵為’被使 用作為α-醯氨基骑(II)的化合物,為一化合物,其中 R3為一個至六個碳原子的烷基族。 :—,---装,------ir------線.-I (請先閲讀背面之注意事項再填寫本頁) · Γ · 經濟部中央揉準局貝工消费合作社印裝 本紙張纽適用帽®家揉準(CNS)从胁(21()χ297公羡 -18-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH33296 | 1996-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW407152B true TW407152B (en) | 2000-10-01 |
Family
ID=4184613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW086101034A TW407152B (en) | 1996-02-09 | 1997-01-30 | Process for the preparation of 4-oxoimidazolinium salts |
Country Status (18)
Country | Link |
---|---|
US (1) | US5698704A (zh) |
EP (1) | EP0789019B1 (zh) |
JP (1) | JP4224629B2 (zh) |
KR (1) | KR100490220B1 (zh) |
CN (1) | CN1071747C (zh) |
AT (1) | ATE202090T1 (zh) |
CA (1) | CA2196263C (zh) |
CZ (1) | CZ291500B6 (zh) |
DE (1) | DE59703745D1 (zh) |
DK (1) | DK0789019T3 (zh) |
ES (1) | ES2158385T3 (zh) |
GR (1) | GR3036558T3 (zh) |
HU (1) | HU225694B1 (zh) |
NO (1) | NO306674B1 (zh) |
PL (1) | PL191419B1 (zh) |
PT (1) | PT789019E (zh) |
SK (1) | SK282845B6 (zh) |
TW (1) | TW407152B (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU218681B (hu) * | 1997-07-25 | 2000-10-30 | Sanofi-Synthelabo | Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek |
HU218680B (hu) * | 1997-07-25 | 2000-10-30 | Sanofi-Synthelabo | Eljárás 1,3-diaza-spiro[4,4]non-1-én-4-on-származékok előállítására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek |
JP2002507611A (ja) * | 1998-03-25 | 2002-03-12 | ブリストル−マイヤーズ スクイブ カンパニー | イミダゾロン食欲抑制薬:ii.フェニル誘導体 |
EP0945441A3 (de) * | 1998-03-27 | 2002-07-17 | Degussa AG | Verfahren zur Herstellung von cyclischen 4-Oxoamidinen |
US5910595A (en) * | 1998-06-26 | 1999-06-08 | Salsbury Chemicals, Inc. | Process for preparing oximidazoles |
JP4505329B2 (ja) * | 2002-09-04 | 2010-07-21 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害薬 |
US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
US9422285B2 (en) | 2013-08-08 | 2016-08-23 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof |
CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
US9771360B2 (en) | 2014-03-21 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use |
CA2969265A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
CA2969268A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
CN107567446A (zh) | 2015-02-05 | 2018-01-09 | 拜耳制药股份公司 | 取代的吡唑并[1,5‑a]吡啶‑3‑甲酰胺及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4709036A (en) * | 1985-06-13 | 1987-11-24 | American Cyanamid Company | Process for the preparation of herbicidal 2-(4,4-disubstituted-5-oxo-2-imidazolin-2-yl)benzoic, nicotinic and quinoline-3-carboxylic acids, esters and salts |
IE910913A1 (en) * | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
JPH06510762A (ja) * | 1991-08-19 | 1994-12-01 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | アンジオテンシン2受容体遮断イミダゾリノン誘導体 |
-
1997
- 1997-01-29 CA CA002196263A patent/CA2196263C/en not_active Expired - Fee Related
- 1997-01-30 TW TW086101034A patent/TW407152B/zh not_active IP Right Cessation
- 1997-01-31 JP JP01815397A patent/JP4224629B2/ja not_active Expired - Fee Related
- 1997-02-03 US US08/794,641 patent/US5698704A/en not_active Expired - Lifetime
- 1997-02-05 CN CN97102520A patent/CN1071747C/zh not_active Expired - Fee Related
- 1997-02-05 SK SK160-97A patent/SK282845B6/sk not_active IP Right Cessation
- 1997-02-06 KR KR1019970003797A patent/KR100490220B1/ko not_active IP Right Cessation
- 1997-02-07 EP EP97102004A patent/EP0789019B1/de not_active Expired - Lifetime
- 1997-02-07 PT PT97102004T patent/PT789019E/pt unknown
- 1997-02-07 CZ CZ1997386A patent/CZ291500B6/cs not_active IP Right Cessation
- 1997-02-07 DK DK97102004T patent/DK0789019T3/da active
- 1997-02-07 HU HU9700380A patent/HU225694B1/hu not_active IP Right Cessation
- 1997-02-07 DE DE59703745T patent/DE59703745D1/de not_active Expired - Lifetime
- 1997-02-07 ES ES97102004T patent/ES2158385T3/es not_active Expired - Lifetime
- 1997-02-07 AT AT97102004T patent/ATE202090T1/de active
- 1997-02-07 NO NO970581A patent/NO306674B1/no not_active IP Right Cessation
- 1997-02-07 PL PL318370A patent/PL191419B1/pl not_active IP Right Cessation
-
2001
- 2001-09-06 GR GR20010401412T patent/GR3036558T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
HU9700380D0 (en) | 1997-03-28 |
JP4224629B2 (ja) | 2009-02-18 |
PL191419B1 (pl) | 2006-05-31 |
HUP9700380A3 (en) | 1998-04-28 |
NO970581L (no) | 1997-08-11 |
PT789019E (pt) | 2001-11-30 |
HUP9700380A2 (en) | 1997-10-28 |
PL318370A1 (en) | 1997-08-18 |
CZ291500B6 (cs) | 2003-03-12 |
NO970581D0 (no) | 1997-02-07 |
CA2196263C (en) | 2004-10-26 |
KR970061874A (ko) | 1997-09-12 |
HU225694B1 (en) | 2007-06-28 |
NO306674B1 (no) | 1999-12-06 |
DE59703745D1 (de) | 2001-07-19 |
EP0789019A1 (de) | 1997-08-13 |
JPH09227527A (ja) | 1997-09-02 |
SK282845B6 (sk) | 2002-12-03 |
DK0789019T3 (da) | 2001-09-03 |
CN1071747C (zh) | 2001-09-26 |
ATE202090T1 (de) | 2001-06-15 |
US5698704A (en) | 1997-12-16 |
CZ38697A3 (en) | 1997-08-13 |
GR3036558T3 (en) | 2001-12-31 |
KR100490220B1 (ko) | 2005-09-08 |
CN1162595A (zh) | 1997-10-22 |
SK16097A3 (en) | 1997-09-10 |
ES2158385T3 (es) | 2001-09-01 |
EP0789019B1 (de) | 2001-06-13 |
CA2196263A1 (en) | 1997-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW407152B (en) | Process for the preparation of 4-oxoimidazolinium salts | |
TW458961B (en) | Amino acid-derived diaminopropanols | |
TWI282337B (en) | Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity | |
CA1048503A (en) | Method of preparing new derivatives of d, l-tyrosine having a pharmaceutical activity on smooth muscles | |
NO176437B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-aminotetralinderivater | |
SK580690A3 (en) | Isoindolone derivatives, process of their preparation and their use as intermediate products | |
JPWO2004113307A1 (ja) | ピリミジン−4−オン化合物の製造方法 | |
HRP20050993A2 (en) | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors | |
ES2217748T3 (es) | Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas. | |
AU644295B2 (en) | 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics | |
Boehm et al. | Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist leucettamine A and related analogs | |
SU512702A3 (ru) | Способ получени производных индазола | |
JP2007508303A (ja) | メラニン凝集ホルモン拮抗物質 | |
CN102093258B (zh) | 芳香型二脒化合物及其合成方法 | |
MXPA02000867A (es) | Proceso para la hidrogenacion catalitica cis selectiva de ciclohexilidenaminas. | |
TW426656B (en) | N-substituted cis-N-propenyl-acetamides, and process for their preparation | |
Butković et al. | Complete 1H and 13C NMR spectral assignment of cis‐and trans‐3‐{2‐[2‐(4‐methylphenyl) ethenyl] phenyl]} sydnones | |
Markov et al. | 5', 6', 7', 8'-Tetrahydro-1'H, 3'H-spiro [cyclohexane-1, 2'-quinazolin]-4'-one in Mannich reaction | |
Bílek et al. | Synthesis of some symmetrically substituted compounds derived from 1, 3‐bis (6‐azauracil‐1‐yl) benzene and 1, 3, 5‐tris (6‐azauracil‐1‐yl) benzene | |
CA2501798A1 (en) | Preparation of triazospiro compounds | |
Connor et al. | Synthesis of 1, 2, 3, 4‐tetrahydro‐5H‐[1] benzopyrano [3, 4‐c] pyridin‐5‐ones. II. Substitution at the 3‐position with 2‐aminoethyl and 2‐aminopropyl side chains | |
Malmberg et al. | The synthesis of 2-and 3-substituted naphth [1, 2] imidazoles | |
Matsumoto et al. | Fischer indole synthesis in the absence of a solvent | |
JPS61205260A (ja) | 新規な2−置換アミノ−6−(2−メトキシフエニ−ル)−4(3h)−ピリミドン誘導体及びその製造法 | |
SU497773A3 (ru) | Способ получени производных индазола |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |